Focused On-demand Library for GTPase IMAP family member 1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We employ our advanced, specialised process to create targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q8WWP7

UPID:

GIMA1_HUMAN

Alternative names:

Immunity-associated protein 1

Alternative UPACC:

Q8WWP7; B2RCI3; Q8NAZ0

Background:

GTPase IMAP family member 1, also known as Immunity-associated protein 1, plays a crucial role in the immune system. It is instrumental in regulating lymphocyte survival, ensuring the presence of mature T-lymphocytes and B-cells, which are vital for the body's defense mechanisms. This protein's function highlights its significance in maintaining immune homeostasis and proper lymphocyte development.

Therapeutic significance:

Understanding the role of GTPase IMAP family member 1 could open doors to potential therapeutic strategies. Its pivotal role in lymphocyte survival and maturation suggests that modulating its activity could offer new avenues for treating immune-related disorders, enhancing immune responses, or potentially correcting immune deficiencies.